Literature DB >> 29720425

Canonical TGF-β Signaling Pathway Represses Human NK Cell Metabolism.

Vanessa Zaiatz-Bittencourt1, David K Finlay2,3, Clair M Gardiner2.   

Abstract

Cytokines stimulate rapid metabolic changes in human NK cells, including increases in both glycolysis and oxidative phosphorylation pathways. However, how these are subsequently regulated is not known. In this study, we demonstrate that TGF-β can inhibit many of these metabolic changes, including oxidative phosphorylation, glycolytic capacity, and respiratory capacity. TGF-β also inhibited cytokine-induced expression of the transferrin nutrient receptor CD71. In contrast to a recent report on murine NK cells, TGF-β-mediated suppression of these metabolic responses did not involve the inhibition of the metabolic regulator mTORC1. Inhibition of the canonical TGF-β signaling pathway was able to restore almost all metabolic and functional responses that were inhibited by TGF-β. These data suggest that pharmacological inhibition of TGF-β could provide a metabolic advantage to NK cells that is likely to result in improved functional responses. This has important implications for NK cell-based cancer immunotherapies.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29720425     DOI: 10.4049/jimmunol.1701461

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

Review 1.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 2.  Lipid Metabolism in Tumor-Associated Natural Killer Cells.

Authors:  Yu Chen; Meihua Sui
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

Authors:  Jaco A C van Bruggen; Anne W J Martens; Joseph A Fraietta; Tom Hofland; Sanne H Tonino; Eric Eldering; Mark-David Levin; Peter J Siska; Sanne Endstra; Jeffrey C Rathmell; Carl H June; David L Porter; J Joseph Melenhorst; Arnon P Kater; Gerritje J W van der Windt
Journal:  Blood       Date:  2019-05-10       Impact factor: 22.113

4.  Role of NK Cells in Tumor Progression.

Authors:  Iñigo Terrén; Francisco Borrego
Journal:  Exp Suppl       Date:  2022

Review 5.  Overcoming TGFβ-mediated immune evasion in cancer.

Authors:  Daniele V F Tauriello; Elena Sancho; Eduard Batlle
Journal:  Nat Rev Cancer       Date:  2021-10-20       Impact factor: 60.716

Review 6.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

Review 7.  TGF-β links glycolysis and immunosuppression in glioblastoma.

Authors:  Lingli Gong; Li Ji; Daxing Xu; Jingjing Wang; Jian Zou
Journal:  Histol Histopathol       Date:  2021-07-29       Impact factor: 2.303

Review 8.  Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy.

Authors:  Chloe Choi; David K Finlay
Journal:  Stem Cell Res Ther       Date:  2021-06-05       Impact factor: 6.832

Review 9.  Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance.

Authors:  Javier Traba; Michael N Sack; Thomas A Waldmann; Olga M Anton
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

10.  UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.

Authors:  Yasuyuki Sera; Yuichiro Nakata; Takeshi Ueda; Norimasa Yamasaki; Shuhei Koide; Hiroshi Kobayashi; Ken-Ichiro Ikeda; Kohei Kobatake; Masayuki Iwasaki; Hideaki Oda; Linda Wolff; Akinori Kanai; Akiko Nagamachi; Toshiya Inaba; Yusuke Sotomaru; Tatsuo Ichinohe; Miho Koizumi; Yoshihiko Miyakawa; Zen-Ichiro Honda; Atsushi Iwama; Toshio Suda; Keiyo Takubo; Hiroaki Honda
Journal:  Blood       Date:  2021-02-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.